Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "Double diabetes" in the diabetes control and complications trial

Diabetes Care

Volumn 30, Issue 3, 2007, Pages 707-712

  Kilpatrick, Eric S ^a   Rigby, Alan S ^b   Atkin, Stephen L ^c  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; VASCULAR DISEASE; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY SIZE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK;

EID: 33847611626     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1982     Document Type: Article

References (41)

1. Reaven G: Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M-R, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
3. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
4. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DSJ, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the west of scotland coronary prevention study. Circulation 108:414-419, 2003
5. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ: Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 112:666-673, 2005
6. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H: The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:5698-5703, 2005
7. World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus: Report of a WHO Consultation. Alwan AKH, Ed. Geneva, World Health Org., 1999, p. 1-59
8. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
9. Balkau B, Charles MA: Comment on the provisional report from theWHOconsultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442-443, 1999
10. Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 23:469-480, 2006
11. DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23:313-319, 1982
12. DeFronzo RA, Hendler R, Simonson D: Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 31:795-801, 1982
13. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G: Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883-887, 1993
14. Teupe B, Bergis K: Epidemiological evidence for "double diabetes." Lancet 337:361-362, 1991
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
16. Williams K, Erbey J, Becker D, Arslanian S, Orchard T: Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626-632, 2000
17. Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Kindey Int 62:963-970, 2002
18. Olson JC, Erbey JR, Forrest KYZ, Williams K, Becker DJ, Orchard TJ: Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism 51:248-254, 2002
19. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Smithline Kinder L, Ellis D, Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diabetes Care 26:1374-1379, 2003
20. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard-Barlund M, Bjorkesten C-Ga, Taskinen M-R, Groop P-H, the FinnDiane Study Group: Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study) Diabetes Care 28:2019-2024, 2005
21. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
22. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703-1720, 1995
23. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75:894-903, 1995
24. Lean MEJ, Han TS, Morrison CE: Waist circumference as a measure for indicating need for weight management. BMJ 311:158-161, 1995
25. Altman DG, Bland J: Time to event (survival) data. Br Med J 317:468-469, 1998
26. Cox DR: Regression models and life-tables (with discussion). J Royal Stat Soc Ser B 34:187-220, 1972
27. Schoenfeld D: Partial residual estimation for the proportional hazards regression model. Biometrika 69:239-241, 1982
28. The GLIM System Release 4. Oxford, Clarendon Press, 1994
29. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL: The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. Diabetes 33:271-276, 1984
30. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760-765, 2003
31. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM: High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the General Practice Research Database. Diabetes Care 29:798-804, 2006
32. Sibley SD, Palmer JP, Hirsch IB, Brunzell JD: Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. J Clin Endocrinol Metab 88:3379-3384, 2003
33. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA 280:140-146, 1998
34. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM: Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 111:2446-2453, 2005
35. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
36. Williams K, Erbey J, Becker D, Orchard T: Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes: the Epidemiology of Diabetes Complications Study. Diabetes Care 22:1084-1091, 1999
37. De Block CEM, De Leeuw IH, Van Gaal LF: Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 28:1649-1655, 2005
38. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
39. Grundy SM: Does the metabolic syndrome exist? Diabetes Care 29:1689-1692, 2006
40. Kahn R: The metabolic syndrome (emperor) wears no clothes. Diabetes Care 29:1693-1696, 2006
41. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H: Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 29:901-907, 2006